TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY
Hormone receptor-positive breast cancer, which expresses the estrogen and/or progesterone receptor, accounts for the majority of cases of breast cancer. Endocrine therapy can be highly effective for patients with these tumors, and identification of those who do not require the addition of chemotherapy is critical. The development of genomic assays has allowed for refinement in predicting the risk for recurrence and the benefit from chemotherapy beyond the use of clinicopathologic features alone for patients with early-stage breast cancer. Additionally, the use of gene expression assays can guide decision-making about the duration of adjuvant endocrine therapy. But despite the existence of a research database and guidelines on the use of genomic assays, vexing questions and clinical challenges remain.

To bridge the gap between research and patient care, this program features a joint discussion with 2 leading breast cancer clinical investigators on the use of genomic classifiers to inform clinical decision-making for patients with early-stage breast cancer. By providing access to the latest scientific developments and the perspectives of leading researchers, this CME activity will assist medical oncologists with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Recognize the evolving application of biomarkers and multigene assays in breast cancer management, and effectively use these tools to refine or individualize treatment plans for patients with localized disease.
• Appreciate the role of adjuvant endocrine therapy versus chemoendocrine therapy for women with ER-positive, HER2-negative, node-negative breast cancer and an intermediate 21-gene Recurrence Score^® (RS).
• Appraise the effects of clinical risk factors, such as tumor size and cancer stage, on the assessment of benefit from chemotherapy by age and RS for patients with early breast cancer.
• Understand the prognostic and predictive impact of the 21-gene assay, and identify patients with early breast cancer who might be appropriate candidates for the test.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THESE CME ACTIVITIES
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Joseph A Sparano, MD
Associate Chairman, Department of Oncology
Montefiore Medical Center
Associate Director for Clinical Research
Albert Einstein Cancer Center
Albert Einstein College of Medicine
Bronx, New York

Advisory Committee: Cardinal Health, CStone Pharmaceuticals, Novartis, Pfizer Inc; Contracted Research: Radius Health Inc; Data and Safety Monitoring Board: Celgene Corporation, Genentech.

Eric P Winer, MD
Senior Vice President for Medical Affairs
Chief, Division of Breast Oncology
Thompson Chair in Breast Cancer Research
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Carrick Therapeutics, Genentech, Genomic Health Inc, GlaxoSmithKline, Jounce Therapeutics, Leap Therapeutics Inc, Lilly, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Genentech, Merck, Novartis.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Genomic Health Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: September 2019
Expiration date: September 2020